RAAS-inhibitorSGLT2-inhibitorheart failurebeta-blockerHFrEFHFmrEFHFpEFHF
…a mineralocorticoid receptor antagonist (MRA), 445 (69.5%) on a RAAS-inhibitor, and 414 (64.7%) on a SGLT2-inhibitor respectively. Overall, 21…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 90 of 2459BBlockerheart failureHFrEFSGL2 InhibitorsNICEARNI
… where only 4 patients had reasons specified for not continuing BBlocker, i.e. bradycardia or poor tolerance. There was no documentation…
Splenic infarcts and abscessessplenic infarctsSplenic abscessesIEinfective endocarditis
… possible and 4% from Duke possible to Duke definite.Conclusion Splenic infarcts and abscesses are an insensitive yet highly specific indicator of IE in patie…
TAVRPubMedatrial fibrillationSurgical aortic valve replacementASSAVRtranscatheter aortic valve replacementEmbase
…rdial infarction rates were comparable at all follow-up points. TAVR markedly reduced new-onset or worsening atrial fibrillation (AF…
diabetesMedicarehypertensionperipheral vascular diseaseImpellaESRDEnd-stage renal disease (ESRD)vasopressorschronic kidney diseasecongestive heart failure+2 more
…scular disease (16.5% vs 11.7%), dyslipidemia (48.1% vs 37.4%), diabetes (69.0% vs 33.9%), prior stroke (6.4% vs 4.1%), prior myocardial…
cancercancer-specificCardiovascular diseaseNHANES
…vs 54.20 years) and EHA (7.79 vs 5.53 years) than those without cancer (both P<0.001), with differences in age-stratified PHA remainin…
cirrhosismetabolic syndromeCKDchronic kidney diseaseWorld Bank
…n/1.73 m2, p<0.0001), associated with a more complex history of cirrhosis complications, with ascites occurring in 76.5% of CKD+ versus 6…
IloprostbosentanSSctertiary SSc referral centre
…nts could reduce the necessity for frequent hospital visits for Iloprost infusions.Further trials to determine which patients can safely…
Mycophenolate Mofetilsystemic sclerosis (SSc)interstitial lung diseaseMMFinterstitial lung disease (ILD)cutaneous fibrosisiloprostlcSScILDIcSSc+3 more
…Introduction The prescription of Mycophenolate Mofetil (MMF) represents the primary treatment for interstitial lung di…
mycophenolate mofetilhydroxychloroquinemethotrexatelcSScinterstitial lung diseasediffuse cutaneous systemic sclerosismyositisCanadian Scleroderma Research Groupmyocarditisarthritis
…ial lung disease (68%). The top first-line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%) and hydroxychloroquine (20%).Conclusi…
systemic sclerosis (SSc)hydroxychloroquineHCQSScHydroxychloroquine (HCQ)Italian Rheumatology centersrheumatic diseases
… for its immunomodulatory properties and is often prescribed in systemic sclerosis (SSc), despite the lack of confirmation of its efficacy in randomized…
mycophenolate mofetilMethotrexatetocilizumababataceptcyclophosphamiderituximabsystemic sclerosisPubMedSScWeb of Science+2 more
…nt systemic treatment in both LS (67.9%) and SSc (48%). In SSc, mycophenolate mofetil (38.1%) and cyclophosphamide (14.1%) were also commonly used. B…